After a placebo run-in phase of four weeks' duration, 1.25 mg or 2.5 mg isradipine twice daily
orally was administered for one year to 23 patients who had been diagnosed as …

After three months of treatment with isradipine, 20 patients with mild hypertension had
reduced their resting blood pressure (BP) from 157/103 to 132/85 mm Hg and their BP …

The antihypertensive effect and safety of treatment of hypertension with isradipine, a Ca
antagonist of dihydropyridine group in monotherapy and in combination with the betablocker …

The antihypertensive effect of isradipine compared with placebo was assessed in 28 male
patients (aged 40–64 years) with mild-to-moderate essential hypertension. After withdrawal …

The antihypertensive effect of isradipine was studied in 35 mild-to-moderate hypertensive
patients (mean age 57 years) using casual and ambulatory 24-h blood pressure …

Eight hundred seventy-six men and women with diastolic blood pressure (DBP) of 95–115
mm Hg during a 4-week placebo period were included in a multicenter trial; 479 patients …

The safety and efficacy of isradipine as well as its long-term effects on renal hemodynamics
were evaluated in a study of 17 patients with mild-to-moderate essential hypertension and …

One-year open Multicentric Isradipine Study (MIS) performed in 7 centres in Czechoslovakia
included 144 patients with mild and moderate hypertension. Isradipine was given at a dose …

The objective of this study was to compare the effects of isradipine and placebo on blood
pressure (BP) at the end of the dosing interval ('trough'). Following a three-week placebo …

The hypotensive effect of isradipine was assessed in 26 male patients, aged 40 to 64 years,
with hypertension. After withdrawal of previous antihypertensive treatment and a four-week …